Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clopidogrel--statin interaction.

James J Nawarskas1

  • 1University of New Mexico, College of Pharmacy, Albuquerque, NM., USA. nawarska@unm.edu

Cardiology in Review
|August 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Need for Competency-Based Education.

American journal of pharmaceutical education·2024
Same author

Recommendations and Next Steps For Competency-Based Pharmacy Education.

American journal of pharmaceutical education·2023
Same author

Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.

Cardiology in review·2023
Same author

Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?

Cardiology in review·2020
Same author

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?

Cardiology in review·2020
Same author

Nitrosamine Impurities in Angiotensin Receptor Blockers.

Cardiology in review·2020
Same journal

Immunometabolism in Cardiovascular Disease: Linking Metabolic Reprogramming to Inflammation, Atherothrombosis, and Clinical Outcomes.

Cardiology in review·2026
Same journal

Cardiotoxicity of Antibody-Drug Conjugates in HER2-Positive Cancer: Beyond Left Ventricular Ejection Fraction Decline.

Cardiology in review·2026
Same journal

Celiac Disease and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Challenges.

Cardiology in review·2026
Same journal

Valve-Specific Comparative Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists After Surgical Valve Procedures in Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Cardiology in review·2026
Same journal

Growing Heart Valves in Congenital Cardiac Surgery: Mechanisms and Considerations for Tissue-Engineered Heart Valves, Noncryopreserved Homografts, and Partial Heart Transplantation.

Cardiology in review·2026
Same journal

Implementation Gaps and Limitations of Statin Therapy in Young Adults: Bridging Guideline Recommendations and Real-World Practice.

Cardiology in review·2026
See all related articles

Concerns exist about statins interfering with clopidogrel activation, potentially increasing thrombotic events. However, current evidence does not support changing prescribing patterns due to this potential drug interaction.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Interactions

Background:

  • Concerns exist regarding HMG CoA reductase inhibitors (statins) potentially inhibiting clopidogrel activation.
  • This interaction could increase the risk of thrombotic events in patients.

Observation:

  • Ex vivo studies have yielded conflicting results on the statin-clopidogrel interaction.
  • More recent retrospective studies suggest no increased thrombotic event rates when statins and clopidogrel are co-administered.
  • These observational studies compared patients on clopidogrel with a statin versus clopidogrel alone.

Findings:

  • The evidence from retrospective studies does not demonstrate a significant increase in myocardial infarction or stroke rates.
  • In vitro and retrospective data present a complex picture of the interaction's clinical significance.

Related Experiment Videos

  • A definitive conclusion awaits prospective studies evaluating combined versus monotherapy administration.

    • Implications:

    • The current body of evidence does not warrant altering prescribing habits solely to avoid a potential statin-clopidogrel interaction.
    • Further prospective research is needed to definitively resolve the debate on the clinical relevance of this drug interaction.
    • Clinicians should weigh the established benefits of statins and clopidogrel against the currently unproven risks of their co-administration.